Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Robinhood Markets, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.03 (market cap $39.89B), while Robinhood Markets, Inc. trades at $111.21 (market cap $100.52B). The key difference: Robinhood Markets, Inc. is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | HOOD | |
|---|---|---|
Market Cap | $39.89B | $100.52B |
Sector | Health | Technology |
52-Week High | $491.22 | $152.46 |
52-Week Low | $278.09 | $65.16 |
Enterprise Value | $38.15B | $101.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Robinhood (HOOD) trades at $111.97, down 2.73% on the day, with a bullish technical outlook supported by moving averages and strong support at $109. The company shows robust fundamentals with 2025 revenue of $4.47 billion and net income of $1.88 billion, though valuation ratios remain elevated with a P/E of 54.35. Recent news highlights growth initiatives including a Trump Accounts program and AI integration in fintech.
Outlook remains positive with 73% analyst buy ratings and a $112.44 consensus target, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is key, with Q2 2026 results expected to drive near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
